Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
1.71B
Market cap1.71B
Price-Earnings ratio
-3.68
Price-Earnings ratio-3.68
Dividend yield
—
Dividend yield—
Average volume
5.13M
Average volume5.13M
High today
$12.41
High today$12.41
Low today
$11.99
Low today$11.99
Open price
$12.12
Open price$12.12
Volume
1.80M
Volume1.80M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$7.95
52 Week low$7.95

Stock Snapshot

Intellia Therapeutics(NTLA) stock is priced at $12.20, giving the company a market capitalization of 1.71B. It carries a P/E multiple of -3.68.

On 2026-10-07, Intellia Therapeutics(NTLA) stock traded between a low of $11.99 and a high of $12.41. Shares are currently priced at $12.20, which is +1.8% above the low and -1.7% below the high.

Intellia Therapeutics(NTLA) shares are trading with a volume of 1.8M, against a daily average of 5.13M.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $7.95.

In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $7.95.

NTLA News

TipRanks 1d
Barclays starts Intellia at Underweight on expected commercial headwinds

Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating and $8 price target The firm sees headwinds for the company’s late-stage...

TipRanks 2d
Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today

20:23 EDT Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time, mar...

Analyst ratings

50%

of 20 ratings
Buy
50%
Hold
30%
Sell
20%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.